Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Connective and Soft Tissue

Explore clinical trials studying Neoplasms, Connective and Soft Tissue. Study availability and eligibility vary by location and protocol.

2,728 public trials 585 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Connective and Soft Tissue trial results

Completed

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003385

Conditions
Adnexal Diseases, Brenner Tumor, Carcinoma, +26 more
Locations
  • MBCCOP - Hawaii Honolulu, Hawaii, United States
  • Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States
  • Ireland Cancer Center Cleveland, Ohio, United States
View Trial Details
Completed

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

NCT00003322

Conditions
Adnexal Diseases, Brenner Tumor, Carcinoma, +23 more
Locations
  • University of Alabama Comprehensive Cancer Center Birmingham, Alabama, United States
  • CCOP - Greater Phoenix Phoenix, Arizona, United States
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States
View all 67 locations
View Trial Details
Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

NCT00005026

Conditions
Adnexal Diseases, Brenner Tumor, Carcinoma, +23 more
Locations
  • University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States
  • Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States
  • Community Hospital of Los Gatos Los Gatos, California, United States
  • University of Colorado Cancer Center Denver, Colorado, United States
View all 47 locations
View Trial Details
Completed

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

NCT00441155

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, +6 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
  • Novartis Investigative Site Lyon, France
  • Novartis Investigative Site Milan, MI, Italy
View Trial Details
Completed

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

NCT00003425

Conditions
Adnexal Diseases, Blood Protein Disorders, Breast Cancer, +74 more
Locations
  • Albert B. Chandler Medical Center, University of Kentucky Lexington, Kentucky, United States
  • Marlene & Stewart Greenebaum Cancer Center, University of Maryland Baltimore, Maryland, United States
  • Kimmel Cancer Center of Thomas Jefferson University - Philadelphia Philadelphia, Pennsylvania, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Completed

RAD001 in Advanced Sarcoma

NCT01830153

Conditions
Bone Diseases, Bone Neoplasms, Bone Sarcomas, +7 more
Locations
  • Seoul National University Bundang Hospital Seongnam-si, Gyeonggi-do, South Korea
  • Asan Medical Center, University of Ulsan College of Medicine Seoul, N/A = Not Applicable, South Korea
  • Yeongnam University College of Medicine Daegu, South Korea
  • Chungnam National University Hospital Daejeon, South Korea
View Trial Details

Related conditions